<DOC>
	<DOCNO>NCT02608073</DOCNO>
	<brief_summary>This study evaluate efficacy , safety , tolerability , effect quality life oral capecitabine combination intravenous ( IV ) cisplatin participant metastatic nasopharyngeal cancer . Participants receive 8 cycle capecitabine treatment , cisplatin administer first day cycle . The anticipated time study treatment 24 week , target sample size 44 individual .</brief_summary>
	<brief_title>A Study Capecitabine ( Xeloda ) First-Line Chemotherapy Participants With Metastatic Nasopharyngeal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Adults 18 75 year age Histologically confirm , poorly differentiate undifferentiated metastatic nasopharyngeal cancer least 1 measurable lesion irradiate Ability swallow retain oral medication Previous cytotoxic chemotherapy except adjuvant , concurrent , neoadjuvant treatment complete least 6 month enrollment Clinically significant cardiac disease History malignancy within last 5 year except cure basal cell cancer skin cure cancer situ cervix Radiotherapy within 4 week treatment start prior radiotherapy perform indicator lesion ( ) measure study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>